

# Covariation of Zinc Deficiency with COVID-19 Infections and Mortality in European Countries: Is Zinc Deficiency a Risk Factor for COVID-19?

Samer Singh<sup>1,2\*</sup>

<sup>1</sup>Centre of Experimental Medicine & Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi – 221005, India

<sup>2</sup>Department of Microbial Biotechnology, Panjab University, Chandigarh – 160014, India

\*Corresponding Author Email ID: [samer.singh10@bhu.ac.in](mailto:samer.singh10@bhu.ac.in); [samer@pu.ac.in](mailto:samer@pu.ac.in); Phone: +91-9161111173

**Abstract:** Variables responsible for the differential COVID-19 pandemic severity among countries remain undefined. Zinc, a micronutrient required for immunocompetence, is found deficient in populations. We hypothesized the differential COVID-19 severity observed among European countries could be associated with the Zn-deficiency prevalence. The COVID-19 data from different stages of pandemic, i.e., 8 April, 12 and 26 May 2020, were analyzed for covariation with the estimated Zn-deficiency. A significant, relatively stable, but negative correlation of Zn-deficiency with cases per million for the time period [ $r(20)$ : -0.4930 to -0.5335,  $p$ -value: 0.02720 to 0.0154] and a steady improvement of covariation with deaths per million [ $r(20)$ : -0.4056;  $p$ -value: 0.0760 on 26 May 2020] was observed. Considering, Zinc's key immunomodulatory role, widespread deficiency along with the self- and prescribed intervention in different target groups, e.g. children, women, elderly, carefully planned dedicated exploratory studies to understand the basis of the observed association are advisable.

**Key Words:** Correlation, Covariation, COVID-19, Europe, micronutrient, SARS-CoV-2, Zinc deficiency

## I. INTRODUCTION

The world is currently in the middle of a novel coronavirus, i.e., SARS-CoV-2 caused COVID-19 pandemic. The damage from COVID-19 had been significant in terms of morbidity and mortality. More than 5.67 million people had been infected and over 351 thousand had already died worldwide by 26 May 2020 while more than 1.93 million infections and over 169 thousand deaths were reported from Europe alone (Worldometers, 2020a). The unprecedented severity of COVID-19 in Europe and North America in contrast to its relatively benign course in the countries of Africa, Asia, South America, and Oceania, had been baffling. Several exploratory studies have been initiated based on assumptions as well as our understanding of coronavirus

biology to identify and establish protective interventions (WHO, 2020a; WHO, 2020b; Wikipedia, 2020). Recently, a protective correlation between Vitamin D serum levels and the cases and the deaths per million from COVID-19 had been indicated in the European countries supposedly having comparable confounding variables and similar health care infrastructure (Ilie, Stefanescu & Smith, 2020; Singh, Kaur & Singh, 2020). The association had been reassuring given the established role of Vitamin D in overall health and the protection offered from acute respiratory tract diseases through an effect on the host's renin-angiotensin system comprising ACEs (Cannell, Vieth, Umhau et al, 2006; Xu, Yang, Chen et al, 2017). Identifying such potential protective variables is highly desirable.

Zinc is essential to good health and immunocompetence. Its deficiency is generally associated with a negative impact on overall health, increased susceptibility to disease, and infections (Prasad, 2013; NIH, 2020; EFSA, 2006; Maares & Haase, 2020). In the absence of reliable methods to assess the Zn status of a population, the deficiency or inadequacy in a population is estimated by combining the dietary intake by a population as per FAO's Food Balance Sheet and the estimated prevalence of stunting (NIH, 2020; EFSA, 2006; Wessells & Brown, 2012; Hess, 2017). Among micronutrients associated with good health, the deficiency of Zinc is quite prevalent ranging from about 5-50 % of the population (Wessells & Brown, 2012). Its high prevalence is associated with increased susceptibility to diseases, mental capacity, complications, high morbidity, and mortality in mothers and neonates (Prasad, 2013; NIH, 2020). Given its role in the overall human health and wellbeing, the countries have tried to overcome the problem through fortification of foods (Prasad, 2013; NIH, 2020; Maares & Haase, 2020; Wessells & Brown, 2012). The countries from the high-income group that consumes a more diverse micronutrient-rich diet are estimated to have Zinc deficiency below 5-10 percent (Wessells & Brown, 2012; Hess, 2017). Incidentally, these had been

the countries also worst affected by COVID-19 (Worldometers, 2020a).

Given the global prevalence of Zinc deficiency and its role in human health as well as the immunocompetence (Prasad, 2013; NIH, 2020; EFSA, 2006; Maares & Haase, 2020), we hypothesized that the incidence of COVID-19 in populations (cases) and the adverse outcomes (deaths) would be directly correlated to Zinc deficiency. The analysis of European countries with comparable underlying confounding variables when performed at different stages of the pandemic was envisioned to provide a more robust indication of the correlation as indicated previously (Singh, Kaur & Singh, 2020). The primary aim of the current study was to identify any correlation between the prevalence of Zinc deficiency with the adverse outcomes in the European countries. Additionally, we intended to identify if it affected the number of cases per unit population or crudely the spread of disease. Surprisingly, our analysis of the selected European countries indicated a consistently negative correlation of Zinc deficiency with COVID-19 cases per million

populations over the time period and indicated an almost significant correlation with the adverse outcome, i.e., death, which seemed improving with the passage of pandemic.

## II. MATERIAL AND METHODS

The European countries with seemingly comparable confounding variables were considered for the analysis as done previously (Ilie, Stefanescu & Smith, 2020; Singh, Kaur & Singh, 2020). The cases and deaths per million population data for COVID-19 from three time-points, i.e., 8 April, 12 May, and 26 May 2020 (Table 1) were collected from <https://www.worldometers.info/coronavirus/> – the coronavirus pandemic data portal. Most of the countries were before COVID-19 infections peak on 8 April 2020 while on 12 and 26 May they were post and late post infections peak stage. The Zinc deficiency estimate data for different countries based on FAO's food balance datasheet and the prevalence of stunting in the countries were obtained from the previously reported estimate by Wessells & Brown, 2012. All basic statistical analysis of

Table 1: COVID-19 pandemic cases and deaths per million population in European Countries with different levels of Zinc deficiency, at three different stages of the current wave of infections.

Countries	% Zn Deficiency (Sufficiency)	8 April 2020 (Most countries before peak)		12 May 2020 (All countries post peak)		26 May 2020 (All countries post peak)	
		Cases/ Million Pop.	Deaths/ Million Pop.	Cases/ Million Pop.	Deaths/ Million Pop.	Cases/ Million Pop.	Deaths/ Million Pop.
Iceland	3.1(96.9)	4736	18	5278	29	5290	29
Norway	6.2(93.8)	1123	19	1500	41	1547	43
Sweden	6.1(93.9)	834	68	2641	322	3412	409
Finland	4.6(95.4)	449	7	1080	49	1196	56
Denmark	6.2(93.8)	933	38	1815	92	1974	97
UK	4.6(95.4)	895	105	3286	472	3909	546
Ireland	4.0(96.0)	1230	48	4685	297	5015	327
Netherlands	5.0(95.0)	1199	131	2497	318	2661	342
Belgium	6.8(93.2)	2019	193	4612	751	4959	806
Germany	9.0(91.0)	1309	25	2060	91	2164	101
France	3.9(96.1)	1671	167	2718	408	2800	437
Switzerland	4.9(95.1)	2686	103	3506	213	3557	221
Italy	5.8(94.2)	2306	292	3636	508	3813	545
Spain	5.4(94.6)	3137	314	5735	572	6060	580
Estonia	10.5(89.5)	893	18	1312	46	1383	49
Czechia	11.0(89.0)	488	9	763	26	845	30
Slovakia	16.3(83.7)	125	0.4	267	5	277	5
Hungary	8.4(91.6)	93	6	340	44	390	52
Turkey	21.7(78.3)	453	10	1657	46	1884	52
Portugal	6.3(93.7)	1289	37	2715	112	3040	132
<b>Average</b>	<b>7.5(92.5)</b>	<b>1393.4</b>	<b>80.4</b>	<b>2605.1</b>	<b>222.1</b>	<b>2808.8</b>	<b>243.0</b>
<b>STDEV</b>	<b>4.5(4.5)</b>	<b>1130.0</b>	<b>94.6</b>	<b>1601.1</b>	<b>221.4</b>	<b>1681.9</b>	<b>238.8</b>

**Note:** All values (cases/deaths per million population, Average, STDEV and % Zinc Deficiency in population) rounded off to the displayed decimal places.

the data, i.e., descriptive, linear regression, calculation of best-fit trend line, Pearson correlation coefficient, and R-squared value ( $R^2$ ) was performed in the Microsoft excel as done previously (Singh, Kaur & Singh, 2020).

### III. RESULTS


A negative correlation between the Zinc deficiency prevalence estimate for the countries and the reported cases of COVID-19 was consistently observed at all three time-points analyzed that covered pre infections peak, i.e., 8 April 2020, and post infections peak, i.e., 12 and 26 May 2020 (see Table 2). The Zinc deficiency of the populations also negatively covaried with adverse

outcomes (mortality) per million populations and the correlation seemed to better with the passage of the current wave of COVID-19 infections. Refer to Table 2 below for the comparative estimate of the correlation and Figure 1 for the correlative regression analysis of the data set ( $R^2=0.3936$  for cases and  $R^2=0.2831$  for deaths per million) on 26 May 2020. An exploratory estimation of the correlation for COVID-19 affected countries of the world that had seemingly comparable exposure to disease, population structure, and health care response as on 12th May 2020 (> 30,000 cases and upwards of 15,000 tests performed per million of the population) and accounted for 63.7% of total cases, namely, Spain, UK, Russia, Italy,

Table 2: Correlation analysis - average Zinc deficiency levels and COVID-19 cases and deaths in select European Countries at different stages of current pandemic

	8 April 2020 (Most countries before peak)	12 May 2020 (All countries post peak)	26 May 2020 (All countries post peak)
Average Cases Per Million Pop. ± STDEV	1393.4 ± 1130.0	2605.2 ± 1601.0	2808.8 ± 1681.9
<b>Correlation: Cases Per Million Pop. vs Zinc deficiency</b>	<b><math>r(20)</math>: -0.4930; <math>p</math> – value: 0.02720</b>	<b><math>r(20)</math>: -0.5335; <math>p</math> – value: 0.0154</b>	<b><math>r(20)</math>: -0.5291; <math>p</math> – value: 0.01644</b>
Average Deaths Per Million Pop. ± STDEV	80.4 ± 94.6	222.1 ± 221.4	243.0 ± 238.8
<b>Correlation: Deaths/M pop. vs Zinc deficiency</b>	<b><math>r(20)</math>: - 0.3652; <math>p</math> – value: 0.1133</b>	<b><math>r(20)</math>: -0.4027; <math>p</math> – value: 0.0784</b>	<b><math>r(20)</math>: -0.4056; <math>p</math> – value: 0.0760</b>
% Zinc Deficiency (Sufficiency) ± STDEV	7.5(92.5) ± 4.5(4.5)		

**Note:** The average COVID -19 cases and deaths per million populations for the countries, and the Zinc deficiency (insufficiency) in the population were rounded off to one decimal place. The correlation estimates and p-values were rounded off to four decimal places.



**Figure 1.** Zinc deficiency in European countries negatively correlated with COVID-19 cases (A) and associated deaths (B) per million population when all countries under study had already passed the peak of current wave of COVID-19 infections (26 May 2020) as per <https://www.worldometers.info/coronavirus/>.

France, Germany, Belgium, Netherlands, Switzerland, USA, Canada, seemed reassuring. For these eleven countries, the Zn deficiency prevalence was exponentially correlated to cases per million with  $R^2 = 0.3301$  and more strongly to deaths per million with  $R^2 = 0.4307$  suggesting a supposedly robust correlation and potential biological significance.

#### IV. DISCUSSION

Our analysis identified a negative association between the Zinc deficiency prevalence in the European countries and the COVID-19 impact in terms of cases and deaths per million of population. The observed covariation should be evaluated for its biological significance, if any, by evaluating COVID-19 patient data to allow its potential translation into preventive measures.

In the absence of Zinc storage in the body, its daily intake is required to maintain healthy levels (Prasad, 2013; Maares & Haase, 2020). The recommended daily Zinc intake varies with the age - increasing from 2 mg for newborns to 8 mg for children 9-13 years old. Its recommended intake is 11 mg for >14 years males while 8- 13 mg for females depending upon their physiological status (NIH, 2020) or lower (EFSA, 2006). The countries of Europe and North America have low Zinc deficiency as compared to other parts of the world (Wessells & Brown, 2012; Hess, 2017), rather there exists chances of excessive Zinc intake from food and supplements (NIH, 2020; EFSA, 2006). Considering the associated adverse effect on immunity, lower level of HDL, low copper levels its upper no-observed-adverse-effect level (NOAEL) and tolerable upper intake limit (UL) have been defined by EFSA as daily intake of 50 mg and 25 mg, respectively (EFSA, 2006). For children and adolescents 1-17 years of age, the recommended UL range is 7-22 mg based upon age and body weight. Zinc deficiency is not considered as a concern as for all the age groups the estimated 97.5 percentile of total Zinc intake is closer to the recommended ULs (EFSA, 2006). In the USA, a 20% reduced no adverse effect upper daily limit for Zinc has been suggested, i.e., >40mg for people older than 18 years while for youngers it is from 4-34 mg depending upon the age and body weight (NIH, 2020).

The estimated Zinc deficiency among the European countries, though low, ranged from 3.1 % (Iceland) to 21.7% (Turkey) based upon their dietary preferences (Wessells & Brown, 2012). Countries with a less diverse diet, lower animal protein intake and increased intake of phytate containing diet happen to have a higher prevalence of Zinc deficiency. Generally, the countries with higher Zn deficiency prevalence, e.g., Turkey (21.7%), Slovakia (16.3%), Czechia (11%), Estonia (10.5%),

Germany (9%), Hungary (8.4%), Portugal (6.3%), Denmark (6.2%), Norway (6.2%) had reported lesser no of cases per million population as compared to lower Zinc deficiency prevalence countries, e.g., Iceland (3.1), France (3.9), Ireland (4%), UK (4.6%) Switzerland (4.9%) Spain (5.4%), Italy (5.8%). However, the difference in the rate of deaths reported per million population by the above indicated differentially Zinc deficient countries was lesser.

Worldwide estimates indicate lower adverse outcomes from COVID-19 in children, adolescents, and women (Worldometers, 2020b). The Zinc deficiency in children, adolescents, women, vegetarians, and alcoholics is widespread (NIH, 2020; EFSA, 2006). Among the countries of Europe, the children, adolescents, and women seemed to be relatively less affected (Worldometers, 2020b). These are the same constituents of the population that tend to have higher Zinc needs and associated physiological deficiency in the body and have a higher prevalence of Zinc deficiency as compared to the estimated deficiency prevalence in the population (NIH, 2020; EFSA, 2006; Maares & Haase, 2020; Wessells & Brown, 2012; Hess, 2017). Interestingly, women appear to be more protected from COVID-19 than males in European countries (Worldometers, 2020b). The COVID-19 associated mortality in women is estimated to be about two-fold lower than that in men. Remarkably, women tend to have a higher prevalence of Zinc deficiency deviating about two fold from that estimated for a population as per surveys performed in low and middle-income countries (Hess, 2017). The relationship may be coincidental or causal only later studies can reveal.

Elderly people (>60-65 years) in Europe had been affected most by COVID-19. Although there is insufficient data to reliably estimate the Zinc deficiency in the elderly, it is perceived to be quite prevalent in the elderly with less than 50% of daily recommended intake being common (Mocchegiani, Romeo, Malavolta et al, 2013). Despite the lower Zinc levels in elderly, the altered Zn homeostasis (lower intercellular availability), altered interplay with copper and Iron homeostasis, the supposed immunosenescence and Zinc level alteration as a result of fortification, supplementation, and medication (NIH, 2020; EFSA, 2006; Maares & Haase, 2020) along with other underlying pathologies could be responsible for the relatively higher mortality in the elderly (Worldometers, 2020b). The existence of potential correlations may be established by future epidemiological studies.

#### V. CONCLUSION

A negative correlation between Zinc deficiency and the COVID-19 infections and mortality is observed in European countries. The basis as well as biological

significance of such an observation, if any, is unknown. Carefully designed studies investigating the basis of increased vulnerability of target groups and the elderly could reveal the role of Zinc and other key micronutrients such as Cu, Fe and Se in COVID-19 and may help devise better strategies for future COVID-19 control. If the observed correlation is to be believed as having cause and effect relationship, it may be predicted that the inherently or transiently higher Zinc levels resulting from supplementation or medication may be associated with higher COVID-19 infections and mortality in patients. A scrutiny of the COVID-19 patients' data for potential Zinc status alteration, such as resulting from the intake of vitamin C, organic acids, animal protein, phytate content along with Zinc supplementation and the administration of Zn status altering drugs such as Hydroxychloroquine would shed light on the biological significance of the observed covariation of the prevalence of Zinc deficiency with COVID-19 cases and mortality in different target populations and its potential preventive role. So, more evidence-gathering follow-up exercises for the closer scrutiny of the COVID-19 patients' medical records, including the micronutrient supplementation and food consumption details is advisable to ascertain the role of Zinc or other key micronutrients on COVID-19 pandemic and potentially find an early solution to COVID-19.

*Author Contributions Statement:* SS conceived the idea and written the manuscript.

*Competing Interests Statement:* There is no conflict of interest with any person or entity to disclose.

*Ethical Statement:* The study complied with the existing ethical standards.

## ACKNOWLEDGMENT

No specific source of funding was utilized for the current study. However, SS acknowledges the funding support from Banaras Hindu University to his laboratory.

## REFERENCES

Cannell, J.J., Vieth, R., Umhau, J.C. et al (2006). Epidemic influenza and vitamin D. *Epidemiol Infect* 356:1129–1140. <https://doi.org/10.1017/S0950268806007175>

EFSA (European Food Safety Authority). 2006. Tolerable upper intake levels for vitamins and minerals. Available: <http://www.efsa.europa.eu/en/ndatopics/docs/ndatolerableuil.pdf> (Accessed on May 30, 2020)

Hess, S.Y. (2017). National Risk of Zinc Deficiency as Estimated by National Surveys. *Food and Nutrition Bulletin*, 38(1) 3-17

Ilie, P.C., Stefanescu, S., Smith, L. (2020). The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. *Aging Clinical and Experimental Research*, 32:1195–1198. <https://doi.org/10.1007/s40520-020-01570-8>

Maares, M., Haase, H. (2020). A Guide to Human Zinc Absorption: General Overview and Recent Advances of In Vitro Intestinal Models. *Nutrients*, 12(3). pii: E762. doi: 10.3390/nu12030762.

Mocchegiani, E., Romeo, J., Malavolta, M., Costarelli, L., Giacconi, R., Di'az, L.E., et al. (2013). Zinc: dietary intake and impact of supplementation on immune function in elderly. *Age (Dordr)*, 35(3): 839-60

NIH Office of Dietary Supplements (ODS). Zinc: Fact Sheet for Health Professionals. Retrieved on 27 May 2020 from <https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/> (Updated on March 6, 2020)

Prasad, A. S. (2013). Discovery of Human Zinc Deficiency: Its Impact on Human Health and Disease. *Advances in Nutrition*, 4(2), 176-190. Available at: <https://academic.oup.com/advances/article/4/2/176/4591626>

Singh, S., Kaur, R., Singh R K. (2020). Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak. *Aging Clin Exp Res* 2020; 32:1609–1612. doi: 10.1007/s40520-020-01619-8

Xu, J., Yang, J., Chen, J., Luo, Q., Zhang, Q., & Zhang, H. (2017). Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. *Molecular Medicine Reports*, 16, 7432-7438. <https://doi.org/10.3892/mmr.2017.7546>

Wessells, K. R., & Brown, K. H. (2012). Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting. *PloS one*, 7(11): e50568

WHO. (2020a). Draft landscape of COVID-19 candidate vaccines. <https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines> (Accessed on 17 May 2020)

WHO. (2020b). A COORDINATED GLOBAL RESEARCH ROADMAP: 2019 NOVEL CORONAVIRUS. [https://www.who.int/blueprint/priority-diseases/key-action/Coronavirus\\_Roadmap\\_V9.pdf?ua=1](https://www.who.int/blueprint/priority-diseases/key-action/Coronavirus_Roadmap_V9.pdf?ua=1) (Accessed on

17 May 2020)

Wikipedia. (2020). COVID-19 drug development.  
[https://en.wikipedia.org/wiki/COVID-19\\_drug\\_development](https://en.wikipedia.org/wiki/COVID-19_drug_development)

Worldometers. (2020a). COVID-19 Coronavirus Pandemic.  
<https://www.worldometers.info/coronavirus/> (Accessed on 27 May 2020)

Worldometers. (2020b). COVID-19 Coronavirus / Age.  
<https://www.worldometers.info/coronavirus/coronavirus-age-sex-demographics/> (Accessed on 27 May 2020)